* Sol-Gel Technologies (NASDAQ:SLGL [https://seekingalpha.com/symbol/SLGL]) said on Thursday that Health Canada has issued [https://seekingalpha.com/pr/20220823-sol-gel-announces-health-canada-approval-of-epsolay] a Notice of Compliance for EPSOLAY for the treatment of inflammatory lesions of rosacea in adults.
* This approval comes as a result of Sol-Gel’s partnership with Searchlight Pharma, Sol-Gel’s exclusive licensee for commercializing EPSOLAY in the Canadian market.
* Under the exclusive license agreement signed in 2023, Searchlight was responsible for obtaining Canadian regulatory approval for EPSOLAY, and with this milestone achieved, Searchlight is preparing to launch EPSOLAY for rosacea patients in Canada.
* As part of the agreement, Sol-Gel is eligible to receive up to $11M in combined potential upfront, regulatory, and sales milestone payments for TWYNEO and EPSOLAY in Canada, in addition to tiered royalties on net sales.
MORE ON SOL-GEL TECHNOLOGIES
* Financial information for Sol-Gel Technologies [https://seekingalpha.com/symbol/SLGL/income-statement]
Sol-Gel announces Health Canada approval of EPSOLAY
Published 2 months ago
Sep 4, 2025 at 11:51 AM
Positive
Auto